OakChart

SAB Biotherapeutics Inc

SABSHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 3:59 PM ET

3.11+0.04 (1.30%)
2026-11-11 22:45 CET
Market cap
276.57 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-66.51 USD m
Free cash flow, TTM
-58.76 USD m
EPS diluted, TTM
-1.69
P/E
-
Compare

Price

SABS against its 20, 50 and 200-day averages
2050200beatmissearnings
2.503.003.504.004.503.0M6.0MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26SABSclose 3.1120-day 2.9950-day 3.15200-day 3.643.1152w low

39.6% under the 52-week high of 5.15 on 12 Mar 2026. 52-week low 2.44 on 19 Oct 2026. Last 15 sessions, 23.0% high to low

Volume 1.41× normal · the line is the 50-bar volume average

Profile

SABS
52-week range, 25% of the way up
2.445.15

SAB Biotherapeutics, Inc. is a clinical-stage, biopharmaceutical company, which engages in advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. It produces human polyclonal immunotherapies and its versatile DiversitAb platform is applicable for unmet needs in human diseases. The company was founded by Eddie J. Sullivan and Christine E. Hamilton in July 2014 and is headquartered in Miami Beach, FL.

IndexRUT
Employees86
IPOFeb 09, 2021
Beta0.75
ATR, 14d0.21
Rel volume1.41
Short float6.23%
Insider own10.40%
Inst own73.76%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap280.17M
Enterprise Value181.04M
Income-66.51M
Sales0.00M
Book/sh2.31
Cash/sh1.15
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees86
IPOFeb 09, 2021

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B1.34
P/C2.69
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio7.28
Current Ratio7.28
Debt/Eq0.02
LT Debt/Eq0.02
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.69
EPS next Y-0.66
EPS next Q-0.23
EPS this Y-39.16%
EPS next Y40.25%
EPS next 5Y10.78%
EPS past 3/5Y43.07% -
Sales past 3/5Y- -
EPS Y/Y TTM60.70%
Sales Y/Y TTM-100.00%
EPS Q/Q-12.51%
Sales Q/Q-
EarningsNov 05 BMO
EPS/Sales Surpr.12.60% -

Ownership

Insider Own10.40%
Insider Trans0.00%
Inst Own73.76%
Inst Trans0.59%
ROA-31.74%
ROE-35.38%
ROIC-30.89%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA204.03%
SMA50-1.29%
SMA200-14.62%
Trades-

Technical

Shs Outstand91.14M
Shs Float80.72M
Short Float6.23%
Short Ratio9.17
Short Interest5.03M
52W High5.15 -39.61%
52W Low2.44 27.46%
Volatility7.52% 8.01%
ATR (14)0.21
RSI (14)51.54
Beta0.75
Rel Volume1.41
Avg Volume548.37K
Volume774,167

Performance

Perf Week-2.20%
Perf Month16.04%
Perf Quarter-17.07%
Perf Half Y-21.46%
Perf YTD-16.84%
Perf Year-4.89%
Perf 3Y-67.95%
Perf 5Y-96.68%
Perf 10Y-
Recom1.08
Target Price11.75
Prev Close3.07
Price3.11
Change %1.30%

Analyst ratings

latest 10 of 10
DateActionAnalystRating changeTargetImplied
Jun 24, 2026InitiatedBBarclaysOverweight$13+318.0%
May 22, 2026InitiatedCCitigroupBuy$11+253.7%
May 20, 2026InitiatedJJefferiesBuy$11+253.7%
Apr 02, 2026InitiatedRRodman & RenshawBuy$13+318.0%
Dec 19, 2025InitiatedGGuggenheimBuy$15+382.3%
Sep 17, 2025InitiatedLLeerink PartnersOutperform$7+125.1%
May 14, 2025ResumedHH.C. WainwrightBuy$10+221.5%
Oct 09, 2024InitiatedCCraig HallumBuy$11+253.7%
Aug 28, 2024InitiatedOOppenheimerOutperform$12+285.9%
Nov 05, 2021InitiatedCChardan Capital MarketsBuy$17+446.6%

Peers

Mkt cap
TickerCompanyMkt cap
ELDNEledon Pharmaceuticals Inc216.97M
SANASana Biotechnology Inc686.16M
CABACabaletta Bio Inc312.79M
KYTXKyverna Therapeutics Inc316.63M
BMEABiomea Fusion Inc44.28M
EQEquillium Inc90.04M
ZURAZura Bio Ltd137.75M
IMVTImmunovant Inc7.67B
IMUXImmunic Inc110.79M
ADMAAdma Biologics Inc2.93B

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
SURISimplify Propel Opportunities ETFAUM: 74.30M
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B

News

latest 14 of 200
  • SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • SAB Biotherapeutics Beats On A Narrower-Than-Expected Loss As SAFEGUARD De-Risks Execution, But Rising Burn Moves The Focus To 2027 Data (Earnings Whispers) -7.55%
  • SAB BIO Reports Q3 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
  • SAB Biotherapeutics Heads Into Q3 With Safeguard Enrollment Clock And Tzield Competition In Focus (Earnings Whispers)
  • SAB BIO to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5, 2026, 08:30 AM ET (GlobeNewswire)
  • SAB BIO to Participate in Chardan 10th Annual Healthcare Conference (GlobeNewswire) -7.09%
  • SAB BIO Receives FDA Fast Track Designation for SAB-142 in Stage 3 Type 1 Diabetes (GlobeNewswire) -5.30%
  • SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress (GlobeNewswire)
  • SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
  • SAB BIO to Participate in Upcoming Investor Conferences (GlobeNewswire)
  • SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... (GuruFocus.com)
  • SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights (GlobeNewswire)
  • SAB BIO to Host Second Quarter 2026 Financial Results Conference Call and Webcast on August 6, 2026, 08:30 AM ET (GlobeNewswire)
  • Breakthrough T1D Awards Grant to Support PRISE-hATG Study of SAB-142 in Stage 3 Type 1 Diabetes (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-05-0.240-0.275-0.2400.000.0010
2026Q22026-08-06-0.280-0.283-0.2820.000.0011
2026Q12026-05-12-0.350-0.213-0.3520.000.007
2025Q42026-03-09-0.244-0.214-0.8130.000.008
2025Q32025-11-13-0.092-0.458-0.2130.000.106
2025Q22025-08-13-1.090-0.796-1.0880.000.135
2025Q12025-05-08-0.560-1.073-0.5590.000.134
2024Q42025-03-31-1.230-1.164-1.2280.100.125
2024Q32024-11-06-1.120-1.106-1.1180.000.125
2024Q22024-08-08-0.790-1.147-0.7930.290.003
2024Q12024-05-20-0.540-0.960-0.5440.940.002
2023Q42024-03-28-3.380-0.620-3.8570.300.002
2023Q32023-11-14-1.000-1.167-0.9740.630.013
2023Q22023-08-21-1.400-1.400-1.3650.100.403
2023Q12023-05-16-1.500-1.133-1.4590.602.543
2022Q42023-01-05-1.800-0.975-1.5635.905.904

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2021FY-6.300-1.925-6.27160.8867.89
2022FY-4.300-3.450-4.30623.9027.64
2023FY-7.640-4.215-7.6422.221.30
2024FY-3.680-3.680-3.6821.321.32
2025FY-0.790-0.382-0.7900.000.00
2026FY--1.099--0.00
2027FY--0.657--0.05
2028FY--0.561--8.66
2029FY--0.363--120.2
2030FY--0.062--265.62

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-058000.000.000.00
2026Q4S2026-08-068000.000.000.00
2026Q4S2026-05-228000.000.000.00
2026Q4S2026-05-197000.000.000.00
2026Q4S2026-05-126000.000.000.00
2026Q4S2026-03-106000.000.000.00
2026Q4S2026-01-286000.000.000.00
2026Q4S2025-12-186010.000.000.00
2026Q4S2025-11-215010.000.000.00
2026Q4S2025-11-144010.000.000.00
2026Q4S2025-11-113000.170.000.50
2026Q4S2025-11-103000.170.000.50
2026Q4S2025-11-093000.170.000.50
2026Q4S2025-11-083000.170.000.50

Estimate history

EPS, annual7.448-6.271-4.306-7.642-3.682-0.794-1.6868
Period202020212022202320242025TTM
EPS, quarterly-1.118-1.228-0.559-1.088-0.213-0.813-0.352-0.282-0.239
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual060.87623.9042.2391.32200
Period202020212022202320242025TTM
Sales, quarterly00.1150000000
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual2.5974.3495.0399.2259.28947.6191.138
Period202020212022202320242025MRQ
Shares, quarterly9.2299.2899.2929.29247.49447.6175.74583.49391.138
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Total Revenue0.000.001.322.2423.9060.880.00
Cost of Goods Sold Incl. D&A3.173.084.793.753.291.650.00
Gross Profit-3.17-3.08-3.47-1.5120.6159.220.00
Selling, General and Administrative Excl. Other81.8745.8739.4436.5749.5372.6234.13
Research and Development58.3334.2730.1616.5236.4457.1827.91
Other Operating Expense0.000.000.000.000.000.000.00
Operating Income-85.04-48.95-42.91-38.08-28.92-13.39-34.68
Interest Expense-0.240.320.320.300.290.47
Unusual Expense-1.70-62.79-58.394.82-10.403.490.00
Net Income Before Taxes-80.5213.27-34.11-42.19-18.72-17.1420.12
Income Taxes0.000.000.000.000.030.000.00
Consolidated Net Income-66.514.26-34.11-42.19-18.74-17.1420.12
Net Income From Continuing Operations-66.514.26-34.11-42.19-18.74-17.1420.12
Net Income-66.514.26-34.11-42.19-18.74-17.1420.12
EPS (Recurring)-1.11-1.51-8.09-7.03-5.98-5.387.45
EPS (Basic, Before Extraordinaries)-0.930.22-3.68-7.64-4.31-6.277.92
EPS (Diluted)-1.69-0.79-3.68-7.64-4.31-6.277.45
EBITDA-81.87-45.87-38.12-34.33-25.63-11.74-34.13
Non-Operating Income (Expense)3.01-0.32-49.261.020.100.0355.27
Other After Tax Adjustments14.02-9.010.000.000.000.000.00
Stock Option Compensation Expense23.315.212.942.422.112.311.30
Price To Earnings Ratio----20.24267.92273.07
Price To Sales Ratio--26.5716.951.073.51-
Gross Margin---262.41-67.2886.2397.28-
Operating Margin---3,244.87-1,700.56-120.97-22.00-
Net Margin---2,579.03-1,884.50-78.40-28.16-
Shares Outstanding91.1447.619.299.235.044.352.60
Market Capitalization276.57276.5735.0235.9725.38115.53117.75

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.000.000.000.000.000.000.11
Cost of Goods Sold Incl. D&A0.820.830.750.760.770.820.780.79
Gross Profit-0.82-0.83-0.75-0.76-0.77-0.82-0.78-0.67
Selling, General and Administrative Excl. Other25.0822.5419.2515.0111.918.919.999.34
Research and Development18.0816.1713.3810.718.956.977.647.63
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-25.90-23.38-20.00-15.77-12.68-9.73-10.77-10.01
Interest Expense-0.060.060.060.040.060.070.07
Unusual Expense-1.651.110.49-1.66-56.750.64-5.032.31
Net Income Before Taxes-22.30-22.49-18.87-16.8645.45-10.11-5.20-11.39
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-22.30-22.49-18.87-2.855.34-10.11-5.20-11.39
Net Income From Continuing Operations-22.30-22.49-18.87-2.855.34-10.11-5.20-11.39
Net Income-22.30-22.49-18.87-2.855.34-10.11-5.20-11.39
EPS (Recurring)-0.25-0.27-0.35-0.84-0.72-1.04-0.94-1.05
EPS (Basic, Before Extraordinaries)-0.24-0.28-0.35-0.060.50-1.09-0.56-1.23
EPS (Diluted)-0.24-0.28-0.35-0.81-0.21-1.09-0.56-1.23
EBITDA-25.08-22.54-19.25-15.01-11.91-8.91-9.99-9.22
Non-Operating Income (Expense)1.952.061.69-2.681.420.330.620.99
Other After Tax Adjustments0.000.000.0014.02-40.110.000.000.00
Stock Option Compensation Expense7.447.255.463.170.800.630.610.67
Price To Sales Ratio----1,364.50142.2233.4426.63
Gross Margin--------585.03
Operating Margin--------8,726.26
Net Margin--------9,934.52
Shares Outstanding91.1483.4975.7447.6147.499.299.299.29
Market Capitalization276.57298.21195.14178.0520.9316.3112.5535.02

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY
Cash & Short Term Investments96.5920.7656.5715.0539.5512.61
Short Term Receivables0.950.050.005.568.0120.57
Inventories0.000.000.000.000.000.00
Other Current Assets3.512.982.341.492.641.28
Total Current Assets101.0523.7958.9122.1050.1934.46
Net Property, Plant & Equipment19.4019.9224.6828.3430.9522.08
Total Investments and Advances46.890.000.000.000.000.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets1.711.87----
Other Assets5.460.480.350.470.000.00
Total Assets174.5246.0683.9450.9081.1456.54
Short Term Debt Incl. Current Port. of LT Debt0.950.811.851.403.101.66
Accounts Payable3.151.690.953.684.467.38
Other Current Liabilities6.585.478.019.9218.902.02
Total Current Liabilities10.687.9810.8114.9926.4611.06
Long Term Debt5.003.864.054.535.426.47
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities1.711.87----
Other Liabilities5.646.3911.770.3210.720.00
Total Liabilities23.0220.0926.6419.8542.5917.53
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.005E-065E-060.000.000.00
Common Equity151.4925.9757.3031.0638.5539.01
Total Shareholders Equity151.4925.9757.3031.0638.5539.01
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity151.4925.9757.3031.0638.5539.01
Total Liabilities & Stockholders Equity174.5246.0683.9450.9081.1456.54
Book Value Per Share3.182.806.216.168.8615.02
Tangible Book Value Per Share3.182.806.216.168.8615.02
Full-Time Employees86635756139-
Price to Book Ratio1.330.952.360.831.081.10
Return on Assets3.86-52.47-62.58-28.39-24.91-
Return on Equity4.80-81.92-95.51-53.85-44.21-
Return on Invested Capital2.72-114.35-68.77-52.66-39.0044.24
Quick Ratio9.462.985.451.471.903.11
Current Ratio9.462.985.451.471.903.11

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY
Net Income-80.5213.27-34.11-42.19-18.74-17.1420.12
Depreciation3.173.084.793.753.291.650.55
Other Funds (Non Cash)26.86-57.45-2.6811.00-7.775.791.29
Funds from Operations-50.49-41.09-31.99-27.45-23.22-9.7021.96
Extraordinary Item0.000.000.000.000.000.000.00
Changes in Working Capital-3.43-3.69-2.302.33-0.2411.68-11.95
Cash from Operating Activities-53.91-44.78-34.29-25.12-23.461.9910.00
Capital Expenditures-4.85-0.93-0.34-0.20-2.17-10.94-12.73
Net Assets From Acquisitions0.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.000.000.040.080.000.01
Purchase or Sale of Investments-61.34-120.77-11.630.000.000.000.00
Purchase of Investments-171.63-142.04-37.450.000.000.000.00
Sale Or Maturity of Investments110.2921.2625.820.000.000.000.00
Other Uses0.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.00
Cash from Investing Activities-66.17-121.71-11.96-0.15-2.09-10.94-12.72
Cash Dividends Paid0.000.000.000.000.000.000.00
Change in Capital Stock273.99168.730.0267.167.760.019.90
Repurchase of Common Pref Stock0.000.000.000.000.000.000.00
Sale of Common Pref Stock273.99168.730.0267.167.760.019.90
Proceedsfrom Stock Options168.73168.730.007.507.680.009.90
Issuance or Reduction of Debt, Net-168.88-0.42-1.17-0.39-1.191.54-0.92
Change in Long Term Debt-168.88-0.42-1.17-0.39-1.191.54-0.92
Issuance of Long Term Debt-168.730.000.250.771.242.840.66
Reduction of Long Term Debt-0.15-0.42-1.42-1.16-2.42-1.30-1.58
Net Financing Active Other Cash Flow0.14-0.01-0.020.00-5.5234.340.00
Other Financing Activities Uses-0.00-0.01-0.020.00-5.520.000.00
Cash from Financing Activities105.25168.30-1.1766.771.0535.898.98
Exchange Rate Effect-0.15-0.21-0.240.02---
Net Change in Cash-14.991.60-47.6741.52-24.5026.936.26
Free Cash Flow-58.76-45.71-34.63-25.32-25.63-8.96-2.73
Preferred Dividends (Cash Flow)----0.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments104.05102.63107.3996.59110.885.71
Short Term Receivables1.501.841.560.950.560.00
Inventories0.000.000.000.000.000.00
Other Current Assets2.193.463.843.511.843.59
Total Current Assets107.74107.94112.78101.05113.289.31
Net Property, Plant & Equipment20.8119.5820.1719.4019.4420.40
Total Investments and Advances101.29105.35110.2446.8950.610.00
Intangible Assets0.000.000.000.000.000.00
Deferred Tax Assets---1.71--
Other Assets5.815.345.285.460.120.42
Total Assets235.64238.21248.47174.52183.4530.13
Short Term Debt Incl. Current Port. of LT Debt0.570.640.920.950.990.96
Accounts Payable2.423.853.543.152.952.62
Other Current Liabilities11.807.215.396.586.857.09
Total Current Liabilities14.8011.719.8510.6810.7910.68
Long Term Debt4.354.495.255.005.205.46
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.71--
Other Liabilities5.587.236.125.642.381.98
Total Liabilities24.7223.4321.2223.0218.3718.11
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.005E-06
Common Equity210.92214.78227.25151.49165.0712.02
Total Shareholders Equity210.92214.78227.25151.49165.0712.02
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity210.92214.78227.25151.49165.0712.02
Total Liabilities & Stockholders Equity235.64238.21248.47174.52183.4530.13
Book Value Per Share2.312.573.003.183.481.29
Tangible Book Value Per Share2.312.573.003.183.481.29
Full-Time Employees---86--
Price to Book Ratio1.331.301.201.081.550.76
Return on Assets-31.74-28.97-18.49-11.62-18.01-80.54
Return on Equity-35.38-34.27-21.31-14.45-21.16-127.48
Return on Invested Capital-10.36-10.26-8.12-1.823.13-57.89
Quick Ratio7.289.2211.459.4610.500.87
Current Ratio7.289.2211.459.4610.500.87

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-22.30-22.49-18.87-16.8645.45-10.11
Depreciation0.820.830.750.760.770.77
Other Funds (Non Cash)5.758.575.916.64-60.881.25
Funds from Operations-15.73-13.08-12.21-9.46-14.67-8.09
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital2.713.24-2.06-7.321.620.94
Cash from Operating Activities-13.02-9.84-14.27-16.78-13.05-7.15
Capital Expenditures-1.34-1.59-0.98-0.930.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.020.000.000.000.000.00
Purchase or Sale of Investments7.39-3.30-64.67-0.77-129.875.20
Purchase of Investments-7.31-13.01-139.26-12.04-129.87-0.05
Sale Or Maturity of Investments14.719.7174.6011.270.005.25
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities6.07-4.88-65.65-1.71-129.875.20
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.00---0.00-
Change in Capital Stock12.892.4189.96168.730.000.00
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock12.892.4189.96168.730.000.00
Proceedsfrom Stock Options0.00-79.6479.64168.730.000.00
Issuance or Reduction of Debt, Net-0.04-0.04-0.04-168.77168.69-0.17
Change in Long Term Debt-0.04-0.04-0.04-168.77168.69-0.17
Issuance of Long Term Debt0.000.000.00-168.73168.730.00
Reduction of Long Term Debt-0.04-0.04-0.04-0.04-0.04-0.17
Net Financing Active Other Cash Flow0.15-0.00-0.00-0.00-0.000.00
Other Financing Activities Uses0.01-0.00-0.00-0.00-0.000.00
Cash from Financing Activities13.002.3689.92-0.04168.69-0.17
Exchange Rate Effect0.120.110.01-0.40-0.040.18
Net Change in Cash6.17-12.2510.02-18.9225.73-1.95
Free Cash Flow-14.37-11.43-15.25-17.71-13.05-7.15

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 1.32M
United States2024: 1.32M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-306.23%5.0M80.7M539.93K
2026-10-155.89%4.8M81.5M525.93K
2026-09-305.26%4.3M81.5M487.32K
2026-09-154.42%3.6M81.5M569.01K
2026-08-315.06%4.1M81.5M666.01K
2026-08-145.68%4.6M81.5M691.29K
2026-07-317.24%4.7M64.4M887.63K
2026-07-156.80%4.4M64.4M871.65K
2026-06-305.86%3.8M64.4M859.11K
2026-06-154.47%2.9M64.4M776.57K
2026-05-294.63%2.6M57.1M785.90K
2026-05-154.81%2.7M57.1M771.54K
2026-04-306.57%2.4M36.8M553.38K
2026-04-158.15%3.0M36.8M570.87K
2026-03-316.80%2.5M36.8M569.62K
2026-03-135.31%2.0M36.8M464.83K
2026-02-274.69%1.6M34.4M354.85K
2026-02-135.41%1.9M34.4M345.64K
2026-01-305.66%1.9M34.4M322.87K
2026-01-154.53%1.6M34.4M294.09K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.000.354.200.000.0000.000.000.964-0.0110.000
call2.000.703.201.1018.7952,2290.000.918-0.0100.001
call3.000.002.300.4514.3204460.000.722-0.0660.002
call4.000.002.150.0514.08396.000.000.837-0.0950.001
call5.000.002.150.0014.8990.000.000.830-0.1030.001
call6.000.002.150.0012.6750.000.000.743-0.1120.002
call7.000.000.950.008.5510.000.000.531-0.0930.002
put1.000.002.150.0010.4250.000.00-0.066-0.0360.001
put2.000.000.050.055.06516.000.00-0.172-0.0350.001
put3.000.000.650.203.7741060.00-0.278-0.0650.002
put4.000.003.000.0013.6080.000.00-0.162-0.0920.001
put5.000.054.000.0014.4810.000.00-0.176-0.1010.001
put6.000.855.000.0015.2480.000.00-0.257-0.1110.002
put7.001.856.000.0015.7640.000.00-0.467-0.0940.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-2225-NSESEC
2026-10-138-KCurrent report2026-10-13SEC
2026-09-184Statement of changes in beneficial ownership of securities2026-09-17SEC
2026-08-21424B3SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-12SCHEDULE 13GSEC
2026-08-10SCHEDULE 13D/ASEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-078-KCurrent report2026-07-07SEC
2026-06-264Statement of changes in beneficial ownership of securities2026-06-25SEC
2026-06-188-KCurrent report2026-06-18SEC
2026-05-15SCHEDULE 13GSEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-15SCHEDULE 13GSEC
2026-05-1210-QQuarterly report pursuant to Section 13 or 15(d)2026-03-31SEC
2026-05-048-KCurrent report2026-04-28SEC
2026-05-01SCHEDULE 13GSEC
2026-04-30DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-06-18SEC
2026-04-228-KCurrent report2026-04-22SEC
2026-03-31S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-03-254Statement of changes in beneficial ownership of securities2026-03-24SEC
2026-03-23SCHEDULE 13D/ASEC
2026-03-198-KCurrent report2026-03-17SEC
2026-03-19424B5SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Caligan Partners LP10.42%
Vivo Capital, LLC9.55%
PERCEPTIVE ADVISORS LLC8.67%
ADAGE CAPITAL PARTNERS GP, L.L.C.8.38%
RA CAPITAL MANAGEMENT, L.P.5.76%
BALYASNY ASSET MANAGEMENT L.P.4.92%
BlackRock, Inc.4.01%
VANGUARD CAPITAL MANAGEMENT LLC3.89%
Commodore Capital LP3.75%
MILLENNIUM MANAGEMENT LLC3.60%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND2.96%
iShares Russell 2000 ETF1.38%
VANGUARD EXTENDED MARKET INDEX FUND0.85%
Fidelity Small Cap Index Fund0.62%
iShares Russell 2000 Value ETF0.50%
Fidelity Extended Market Index Fund0.30%
VANGUARD RUSSELL 2000 INDEX FUND0.27%
iShares Micro-Cap ETF0.19%
Schwab Small-Cap Index Fund0.14%
Fidelity Total Market Index Fund0.14%

OakChart. SABS. Cached 15 minutes.

Some panels did not load: insider.